Innopath Therapeutics develops targeted, patient-friendly topical therapies for actinic keratosis and non-melanoma skin cancers. The company leverages deep scientific expertise and formulation science to address limitations in current dermatologic oncology treatments. Their approach aims to deliver safer, more effective, and accessible solutions for patients with these common skin conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for actinic keratosis and non-melanoma skin cancers often involve painful, visually disruptive, and repetitive procedures. This cycle fails to adequately address cellular damage and can negatively impact overall skin health.
Solution
Innopath Therapeutics is developing topical therapeutics designed to target the earliest stages of actinic keratosis and non-melanoma skin cancers. Our approach leverages specific cellular pathways to precisely identify and address damaged cells while simultaneously promoting healthy skin tissue. This strategy aims to provide a more effective and less invasive therapeutic option for a significant patient population.
Target Audience
The primary target audience includes patients diagnosed with actinic keratosis and non-melanoma skin cancers, as well as dermatologists and oncologists seeking advanced topical treatment modalities.
Features
- Topical formulations targeting cellular pathways for precise treatment of actinic keratosis and non-melanoma skin cancers.
- Mechanism of action focused on eliminating damaged cells while supporting overall skin health.
- Development pipeline for next-generation dermatological therapeutics.